Evotec Collaborates with Korean Entities on Novel Lung Disease Treatments

Evotec SE, in collaboration with Yonsei University and Zymedi, has received a US$ 4.5 million grant from the Korea Institute of Advanced Technology. This funding aims to develop advanced biologic therapies to address lung diseases like asthma and idiopathic pulmonary fibrosis (IPF). This project targets tRNA synthetases, a novel therapeutic focus.

Dr. Thomas Hanke from Evotec emphasized the strength of international collaborations in tackling diseases with high unmet needs. The project promises to leverage Evotec's expertise in antibody development and Zymedi's innovative approach to tRNA synthetases. Prof. Sunghoon Kim of Yonsei University, a leading researcher in the field, will contribute significantly.

This collaboration plans to develop first-in-class antibodies targeting tRNA synthetase biology, aiming to improve treatments for IPF and non-type 2 asthma.